381.36
0.98%
+3.71
Dopo l'orario di chiusura:
381.36
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ISRG Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$377.65
Aprire:
$380
Volume 24 ore:
1.01M
Capitalizzazione di mercato:
$135.27B
Reddito:
$7.32B
Utile/perdita netta:
$1.99B
Rapporto P/E:
89.73
EPS:
4.25
Flusso di cassa netto:
$595.80M
1 W Prestazione:
+1.61%
1M Prestazione:
-0.54%
6M Prestazione:
+36.92%
1 anno Prestazione:
+25.01%
Intuitive Surgical Inc Stock (ISRG) Company Profile
Nome
Intuitive Surgical Inc
Settore
Industria
Telefono
408-523-2100
Indirizzo
1020 Kifer Road, Sunnyvale
Intuitive Surgical Inc Stock (ISRG) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2023-11-17 | Iniziato | HSBC Securities | Buy |
2023-07-19 | Iniziato | Robert W. Baird | Outperform |
2023-04-19 | Reiterato | BTIG Research | Buy |
2023-04-19 | Reiterato | BofA Securities | Buy |
2023-04-19 | Reiterato | Citigroup | Buy |
2023-04-19 | Reiterato | Evercore ISI | In-line |
2023-04-19 | Reiterato | JP Morgan | Overweight |
2023-04-19 | Reiterato | Morgan Stanley | Equal-Weight |
2023-04-19 | Reiterato | RBC Capital Mkts | Outperform |
2023-04-19 | Reiterato | Raymond James | Outperform |
2023-04-19 | Reiterato | Stifel | Buy |
2023-04-19 | Reiterato | Truist | Buy |
2023-04-19 | Reiterato | Wells Fargo | Overweight |
2023-03-29 | Iniziato | UBS | Neutral |
2023-03-23 | Iniziato | William Blair | Outperform |
2022-10-18 | Iniziato | Barclays | Overweight |
2022-10-13 | Iniziato | Mizuho | Neutral |
2022-10-12 | Iniziato | Jefferies | Hold |
2022-04-13 | Iniziato | Truist | Buy |
2022-04-06 | Iniziato | Wolfe Research | Peer Perform |
2022-03-25 | Iniziato | RBC Capital Mkts | Outperform |
2022-03-02 | Ripresa | BofA Securities | Buy |
2022-02-02 | Aggiornamento | UBS | Neutral → Buy |
2022-01-31 | Aggiornamento | Piper Sandler | Neutral → Overweight |
2022-01-25 | Downgrade | Redburn | Buy → Neutral |
2022-01-21 | Reiterato | BTIG Research | Buy |
2022-01-21 | Aggiornamento | Citigroup | Neutral → Buy |
2022-01-21 | Reiterato | Deutsche Bank | Hold |
2022-01-21 | Reiterato | Evercore ISI | In-line |
2022-01-21 | Reiterato | Morgan Stanley | Equal-Weight |
2022-01-21 | Reiterato | Piper Sandler | Neutral |
2022-01-21 | Reiterato | Raymond James | Outperform |
2022-01-21 | Reiterato | Robert W. Baird | Outperform |
2022-01-21 | Reiterato | Stifel | Buy |
2022-01-21 | Reiterato | UBS | Neutral |
2022-01-21 | Reiterato | Wells Fargo | Overweight |
2022-01-10 | Aggiornamento | BTIG Research | Neutral → Buy |
2021-10-01 | Downgrade | Citigroup | Buy → Neutral |
2021-07-21 | Reiterato | BofA Securities | Neutral |
2021-07-21 | Reiterato | Citigroup | Buy |
2021-07-21 | Reiterato | JP Morgan | Overweight |
2021-07-21 | Reiterato | Morgan Stanley | Equal-Weight |
2021-07-21 | Reiterato | Piper Sandler | Neutral |
2021-07-21 | Reiterato | SVB Leerink | Mkt Perform |
2021-07-21 | Reiterato | Stifel | Buy |
2021-07-21 | Reiterato | UBS | Neutral |
2021-07-21 | Reiterato | Wells Fargo | Overweight |
2021-07-14 | Reiterato | Goldman | Buy |
2021-06-01 | Aggiornamento | Evercore ISI | Underperform → In-line |
2021-04-21 | Aggiornamento | Oppenheimer | Underperform → Perform |
2021-04-21 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
2021-04-01 | Iniziato | Citigroup | Buy |
2020-12-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2020-09-28 | Iniziato | Argus | Buy |
2020-09-11 | Iniziato | Wolfe Research | Outperform |
2020-09-08 | Downgrade | BofA Securities | Buy → Neutral |
2020-09-02 | Iniziato | Robert W. Baird | Neutral |
2020-07-20 | Reiterato | Bernstein | Outperform |
2020-04-28 | Downgrade | Piper Sandler | Overweight → Neutral |
2020-04-17 | Downgrade | CFRA | Hold → Sell |
2020-04-17 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
2020-04-09 | Downgrade | Evercore ISI | In-line → Underperform |
2020-04-01 | Downgrade | Oppenheimer | Perform → Underperform |
2020-01-27 | Downgrade | Deutsche Bank | Buy → Hold |
2019-12-12 | Reiterato | Wells Fargo | Outperform |
2019-11-21 | Iniziato | Oppenheimer | Perform |
2019-07-19 | Reiterato | Canaccord Genuity | Buy |
2019-04-22 | Reiterato | Canaccord Genuity | Buy |
2019-04-02 | Iniziato | Deutsche Bank | Buy |
2018-10-31 | Reiterato | Piper Jaffray | Overweight |
2018-10-19 | Aggiornamento | Canaccord Genuity | Hold → Buy |
Mostra tutto
Intuitive Surgical Inc Borsa (ISRG) Ultime notizie
Intuitive Announces Board of Directors Elections and Retirements
GlobeNewswire Inc.
Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know
Zacks Investment Research
Got $500? 3 Healthcare Stocks to Buy and Hold Forever
The Motley Fool
These Analysts Revise Their Forecasts On Intuitive Surgical Following Q1 Results
Benzinga
Intuitive Surgical (ISRG) Q1 Earnings Beat, Procedures Robust
Zacks Investment Research
Wall Street On Track For 6th Day Of Losses? Netflix, Geopolitical Tensions Drag Futures Down: Analyst Tells Why Next 2 Weeks Are Pivotal
Benzinga
Intuitive Surgical Inc Azioni (ISRG) Dati Finanziari
Intuitive Surgical Inc (ISRG) Reddito 2024
ISRG ha riportato un ricavo (TTM) di $7.32 miliardi per il trimestre terminato il 2024-03-31, un +13.81% salita anno su anno.
Intuitive Surgical Inc (ISRG) Reddito netto 2024
ISRG l'utile netto (TTM) è stato di $1.99 miliardi per il trimestre terminato il 2024-03-31, un +51.49% aumento anno su anno.
Intuitive Surgical Inc (ISRG) Flusso di cassa 2024
ISRG ha registrato un flusso di cassa disponibile (TTM) di $595.80 milioni per il trimestre conclusosi con 2024-03-31, un -40.79% diminuire anno su anno.
Intuitive Surgical Inc (ISRG) Utile per azione 2024
L'utile per azione (TTM) di ISRG è stato pari a $5.54 per il trimestre terminato il 2024-03-31, un +51.37% crescita anno su anno.
Intuitive Surgical Inc Azioni (ISRG) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
DeSantis Robert | EVP & Chief Strategy & Corp Op |
Apr 29 '24 |
Option Exercise |
249.61 |
376 |
93,855 |
5,695 |
DeSantis Robert | EVP & Chief Strategy & Corp Op |
Apr 29 '24 |
Sale |
375.39 |
376 |
141,147 |
5,507 |
DeSantis Robert | EVP & Chief Strategy & Corp Op |
Apr 26 '24 |
Option Exercise |
273.00 |
1,498 |
408,950 |
5,903 |
DeSantis Robert | EVP & Chief Strategy & Corp Op |
Apr 26 '24 |
Sale |
369.92 |
1,498 |
554,146 |
5,507 |
Beery Joseph C | Director |
Apr 25 '24 |
Option Exercise |
0.00 |
569 |
0 |
2,371 |
BARRATT CRAIG H | Director |
Apr 25 '24 |
Option Exercise |
0.00 |
804 |
0 |
26,155 |
Reed Monica P | Director |
Apr 25 '24 |
Option Exercise |
0.00 |
569 |
0 |
1,606 |
LEVY ALAN J | Director |
Apr 25 '24 |
Option Exercise |
0.00 |
569 |
0 |
25,888 |
Leonard Keith R | Director |
Apr 25 '24 |
Option Exercise |
0.00 |
569 |
0 |
1,606 |
Ladd Amy L | Director |
Apr 25 '24 |
Option Exercise |
0.00 |
569 |
0 |
1,271 |
Capitalizzazione:
|
Volume (24 ore):